SavedAdd your journal

Journals / Türk Veteriner Cerrahi Dergisi / 2026 / Cilt: 5 Sayı: 1

Stereotactic Radiosurgery in Veterinary Medicine

Veteriner Hekimlikte Stereotaktik Radyocerrahi

Raşit Atakan Taşdemir(BURSA ULUDAĞ ÜNİVERSİTESİ, VETERİNER FAKÜLTESİ)0009-0001-6565-7973
Zeynep Korul(BURSA ULUDAĞ ÜNİVERSİTESİ, VETERİNER FAKÜLTESİ)0009-0002-0426-6829
Gamze Yataz(BURSA ULUDAĞ ÜNİVERSİTESİ, VETERİNER FAKÜLTESİ)0009-0006-3028-4739
Hakan Salcı(Bursa Uludağ Üniversitesi Veteriner Fakültesi)0000-0001-6548-8754
Pages
17–22
Publication Date
2026-07-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review focuses on the physical principles and radiobiological effects of SRS, and aims to provide information about its applications in veterinary neuro-oncology.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Stereotactic radiosurgery (SRS) is a non-invasive and advanced treatment method that allows the delivery of very high doses of radiation with millimeter precision to target tissues in critical areas of the body, particularly the brain.
📊
Key Findings & Data:Compared to conventional radiotherapy, SRS treatment is completed in 1-3 sessions, thus reducing the patient's anesthesia time and treatment-related stress.
💡
Conclusion & Impact:This review focuses on the physical principles and radiobiological effects of SRS, and aims to provide information about its applications in veterinary neuro-oncology.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Nöro-onkoloji · Stereotaktik radyocerrahi · veteriner hekimlik

Abstract

Stereotactic radiosurgery (SRS) is a non-invasive and advanced treatment method that allows the delivery of very high doses of radiation with millimeter precision to target tissues in critical areas of the body, particularly the brain. The basic principle is to combine multiple radiation beams into a single focus to create an ablation effect in the target tissue and minimize the radiation dose to surrounding healthy tissues. In veterinary oncology, SRS is a relatively new treatment method used to treat various tumors, especially intracranial, nasal, and spinal tumors that are difficult to access surgically or carry a high risk. Compared to conventional radiotherapy, SRS treatment is completed in 1-3 sessions, thus reducing the patient's anesthesia time and treatment-related stress. In SRS, the localization of the lesion should be determined before treatment planning using advanced imaging findings such as computed tomography and magnetic resonance imaging. When SRS is used in combination with chemotherapeutic or immunotherapeutic drugs, a significant improvement in patient survival time, prognosis, and quality of life is observed. However, SRS also has potential complications such as cerebral edema, neurological disorders, and late-stage radiation necrosis. This review focuses on the physical principles and radiobiological effects of SRS, and aims to provide information about its applications in veterinary neuro-oncology.

Özet

Stereotaktik radyocerrahi (SRS), özellikle beyin olmak üzere vücudun kritik bölgelerinde yer alan hedef dokulara, milimetrik hassasiyetle çok yüksek dozda radyasyon iletilmesini sağlayan, non-invazif ve ileri bir tedavi yöntemidir. Temel prensip, çoklu radyasyon demetlerini tek bir odakta birleştirerek hedef dokuda ablasyon etkisi oluşturmak ve çevredeki sağlıklı dokuların maruz kaldığı radyasyon dozunu en aza indirmektir. Veteriner onkolojide SRS, cerrahi olarak erişilmesi güç veya yüksek risk taşıyan intrakraniyal, nazal ve spinal tümörler başta olmak üzere çeşitli tümörlerin tedavisinde kullanılan yeni sayılabilecek bir tedavi yöntemidir. Geleneksel radyoterapiye kıyaslandığında, SRS tedavisi 1-3 seansta tamamlanır ve böylece hastanın anestezi süresi ve tedaviye bağlı stresi azaltılmış olur. SRS’de tedavi planlaması öncesinde lezyonun lokalizasyonu bilgisayarlı tomografi ve manyetik rezonans görüntüleme gibi ileri görüntüleme bulguları ile lokalize edilmelidir. SRS, kemoterapötik veya immünoterapötik ilaçlarla birlikte kullanılırsa hastanın sağkalım süresinde uzama, prognoz ve yaşam kalitesinde önemli ölçüde iyileştirme görülür. Ancak SRS’nin serebral ödem, nörolojik bozukluk ve geç dönem radyasyon nekrozu gibi potansiyel komplikasyonları da bulunmaktadır. Bu derlemede SRS’nin fiziksel prensipleri ve radyobiyolojik etkileri üzerinde durularak, veteriner nöro-onkolojik uygulamalar hakkında bilgi verilmeye çalışılmıştır.

🔖

Cite This Article

Taşdemir, R. A., Korul, Z., Yataz, G., Salcı, H. (2026). Stereotactic Radiosurgery in Veterinary Medicine. Türk Veteriner Cerrahi Dergisi, Cilt: 5 Sayı: 1, 17–22. https://ajindex.com/articles/1603451

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (32)

  1. Khaledi N., Khan R., Gräfe J.L.: Historical progress of stereotactic radiation surgery. J. Med. Phys. 2023, 48(4): 312-327.
  2. Steiner L., Lindquist C., Adler J.R., Torner J.C., Alves W., Steiner M.: Clinical outcome of radiosurgery for cerebral arteriovenous malformations. J. Neurosurg. 1992, 77(1): 1-8.
  3. Lunsford L.D., Niranjan A., Kano H., Kondziolka D.: The technical evolution of gamma knife radiosurgery for arteriovenous malformations. Prog. Neurol. Surg. 2013, 27: 22-34.
  4. Lester N.V., Hopkins A.L., Bova F.J., Friedman W.A., Buatti J.M., Meeks S.L., Chrisman C.L.: Radiosurgery using a stereotactic headframe system for irradiation of brain tumors in dogs. J. Am. Vet. Med. Assoc. 2001, 219(11): 1562-1567.
  5. Winston K.R., Lutz W.: Linear accelerator as a neurosurgical tool for stereotactic radiosurgery. Neurosurgery. 1988, 22(3): 454-464.
  6. Rao S.S., Oh J.H., Jackson A., Deasy J.O.: Dose escalation, not “new biology,” can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer. In regard to Brown et al. Int. J. Radiat. Oncol. Biol. Phys. 2014, 89(3): 692-693.
  7. Mangoni M., Borghesi S., Aristei C., Becherini C.: Radiobiology of stereotactic radiotherapy. Rep. Pract. Oncol. Radiother. 2022, 27(1): 57-62.
  8. Song C.W., Lee Y.J., Griffin R.J., Park I., Koonce N.A., Hui S., Kim M.S., Dusenbery K.E., Sperduto P.W., Cho L.C.: Indirect tumor cell death after high-dose hypofractionated irradiation: implications for stereotactic body radiation therapy and stereotactic radiation surgery. Int. J. Radiat. Oncol. Biol. Phys. 2015, 93(1): 166-172.
  9. Stone H.B., Peters L.J., Milas L.: Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J. Natl. Cancer. Inst. 1979, 63(5): 1229-1235.
  10. Lugade A., Moran J.P., Gerber S.A., Rose R.C., Frelinger J.G., Lord E.M.: Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 2005, 174(12): 7516-7523.
  11. Dewan M.Z., Galloway A.E., Kawashima N., Dewyngaert J.K., Babb J.S., Formenti S.C., Demaria S.: Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer. Res. 2009, 15(17): 5379-5388.
  12. Vanpouille-Box C., Alard A., Aryankalayil M.J., Sarfraz Y., Diamond J.M., Schneider R.J., Inghirami G., Coleman C.N., Formenti S.C., Demaria S.: DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat. Commun. 2017, 8: 15618.
  13. Gieger T.L.: Radiation therapy for brain tumors in dogs and cats. Vet. Clin. North. Am. Small. Anim. Pract. 2025, 55(1): 67-80.
  14. Nolan M.W., Gieger T.L.: Update in veterinary radiation oncology: focus on stereotactic radiation therapy. Vet. Clin. North. Am. Small. Anim. Pract. 2024, 54(3): 559-575.
  15. Hall W.A., Das J.M.: Stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). In: StatPearls. Treasure Island (FL): StatPearls Publishing; July 6, 2025.
  16. Purvis T.E., Goodwin C.R., Lubelski D., Laufer I., Sciubba DM.: Review of stereotactic radiosurgery for intradural spine tumors. CNS. Oncol. 2017, 6(2): 131-138.
  17. Carter G.L., Ogilvie G.K., Mohammadian L.A., Bergman P.J., Lee R.P., Proulx D.R.: CyberKnife stereotactic radiotherapy for treatment of primary intracranial tumors in dogs. J. Vet. Intern Med. 2021, 35(3): 1480-1486.
  18. Shaw E., Scott C., Souhami L., Dinapoli R., Kline R., Loeffler J., Farnan N.: Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int. J. Radiat. Oncol. Biol. Phys. 2000, 47(2): 291-298.
  19. Dunfield E.M., Turek M.M., Buhr K.A., Christensen N.I.: A survey of stereotactic radiation therapy in veterinary medicine. Vet. Radiol. Ultrasound. 2018, 59(6): 786-795.
  20. Nolan M.W., Gieger T.L.: Update in veterinary radiation oncology: focus on stereotactic radiation therapy. Vet. Clin. North. Am. Small. Anim. Pract. 2019, 49(5): 933-947.
  21. Rossmeisl J.H Jr., Jones J.C., Zimmerman K.L., Robertson J.L.: Survival time following hospital discharge in dogs with palliatively treated primary brain tumors. J. Am. Vet. Med. Assoc. 2013, 242(2): 193-198.
  22. Heidner G.L., Kornegay J.N., Page R.L., Dodge R.K., Thrall D.E.: Analysis of survival in a retrospective study of 86 dogs with brain tumors. J. Vet. Intern. Med. 1991, 5(4): 219-226.
  23. Griffin L.R., Nolan M.W., Selmic L.E., Randall E., Custis J., LaRue S.: Stereotactic radiation therapy for treatment of canine intracranial meningiomas. Vet. Comp. Oncol. 2016, 14(4): e158-e170.
  24. Kelsey K.L., Gieger T.L., Nolan M.W.: Single fraction stereotactic radiation therapy (stereotactic radiosurgery) is a feasible method for treating intracranial meningiomas in dogs. Vet. Radiol. Ultrasound. 2018, 59(5): 632-638.
  25. Monforte Monteiro S.R., Rossmeisl J.H., Russell J., Holmes M.A., Wessmann A., Morris J., Dobson J.M., Vanhaesebrouck A.E.: Effect of radiotherapy on freedom from seizures in dogs with brain tumors. J. Vet. Intern. Med. 2020, 34(2): 821-827.
  26. Dolera M., Malfassi L., Bianchi C., Carrara N., Finesso S., Marcarini S., Mazza G., Pavesi S., Sala M., Urso G.: Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas. Vet. Comp. Oncol. 2018, 16(1): 90-101.
  27. Dolera M., Malfassi L., Bianchi C., Carrara N., Finesso S., Marcarini S., Mazza G., Pavesi S., Sala M., Urso G.: Immunotherapeutic allogeneic dendritic cell and autologous tumor cell fusion vaccine alone or combined with radiotherapy in canine oral malignant melanoma is safe and potentially effective. Front. Vet. Sci. 2024, 11: 1397518.
  28. Gieger T.L., Nolan M.W.: Treatment outcomes and target delineation utilizing CT and MRI in 13 dogs treated with a uniform stereotactic radiation therapy protocol (16 Gy single fraction) for pituitary masses: (2014-2017). Vet. Comp. Oncol. 2021, 19(1): 17-24.
  29. Wormhoudt T.L., Boss M.K., Lunn K., Griffin L., Leary D., Dowers K., Rao S., LaRue S.M.: Stereotactic radiation therapy for the treatment of functional pituitary adenomas associated with feline acromegaly. J. Vet. Intern. Med. 2018, 32(4): 1383-1391.
  30. Bloomfield R.: Stereotactic radiation therapy in veterinary medicine. Can. Vet. J. 2015, 56(1): 95-97.
  31. Rohrer Bley C., Meier V., Turek M., Besserer J., Unterhirkhers S.: Stereotactic radiation therapy planning, dose prescription and delivery in veterinary medicine: a systematic review on completeness of reporting and proposed reporting items. Vet. Comp. Oncol. 2024, 22(4): 457-469.
  32. Yoshikawa H., Lafferty M.H., Griffin L.R., LaRue S.M.: A retrospective study of sinonasal tumors in 182 dogs treated with stereotactic radiotherapy (3 × 10 Gy) (2010-2015). J. Vet. Intern. Med. 2023, 37(6): 2356-2367.